The NDM-1 biosensor rapidly and accurately detected antibiotic plasma concentrations in Cefuroxime-treated patients
(2024) In International Journal of Antimicrobial Agents- Abstract
Therapeutic drug monitoring (TDM) of β-lactam antibiotics in critically ill patients may benefit dose optimization, thus improving therapeutic outcomes. However, rapidly and accurately detecting these antibiotics in blood remains a challenge. Our research group recently developed a thermometric biosensor called the New Delhi metallo-β-lactamase-1 (NDM-1) biosensor, which detected multiple classes of β-lactam antibiotics in spiked plasma samples. This study assesses the NDM-1 biosensor's effectiveness in detecting plasma concentrations of β-lactam antibiotic in treated patients. Seven patients receiving Cefuroxime were studied. Plasma samples collected pre- and post-antibiotic treatment were analyzed using the NDM-1 biosensor and... (More)
Therapeutic drug monitoring (TDM) of β-lactam antibiotics in critically ill patients may benefit dose optimization, thus improving therapeutic outcomes. However, rapidly and accurately detecting these antibiotics in blood remains a challenge. Our research group recently developed a thermometric biosensor called the New Delhi metallo-β-lactamase-1 (NDM-1) biosensor, which detected multiple classes of β-lactam antibiotics in spiked plasma samples. This study assesses the NDM-1 biosensor's effectiveness in detecting plasma concentrations of β-lactam antibiotic in treated patients. Seven patients receiving Cefuroxime were studied. Plasma samples collected pre- and post-antibiotic treatment were analyzed using the NDM-1 biosensor and compared with liquid chromatography coupled with ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). The biosensor detected plasma samples without dilution, and a brief pre-treatment using a PVDF filter significantly lowered matrix effects, reducing the running time to 5-8 minutes per sample. The assay's linear range for Cefuroxime (6.25 to 200 mg/L) covered target concentrations during the trough phase of pharmacokinetics in critically ill patients. The pharmacokinetic properties of Cefuroxime in treated patients determined by the NDM-1 biosensor and the UPLC-MS/MS were comparable, and the Cefuroxime plasma concentrations measured by the two methods showed a statistically good consistency. These data demonstrate that the NDM-1 biosensor assay is a fast, sensitive, and accurate method for detecting Cefuroximeplasma concentration in treated patients and highlights the NDM-1 biosensor as a promising tool for on-site TDM of β-lactam antibiotics in critically ill patients.
(Less)
- author
- Meng, Qinglai ; Wang, Yao ; Long, Yali ; Wang, Qi ; Gao, Yajing ; Tian, Junsheng ; Wu, Changxin and Xie, Bin LU
- organization
- publishing date
- 2024-05-30
- type
- Contribution to journal
- publication status
- epub
- subject
- in
- International Journal of Antimicrobial Agents
- article number
- 107229
- publisher
- Elsevier
- external identifiers
-
- pmid:38823493
- ISSN
- 1872-7913
- DOI
- 10.1016/j.ijantimicag.2024.107229
- language
- English
- LU publication?
- yes
- additional info
- Copyright © 2024. Published by Elsevier Ltd.
- id
- 7ba9fd36-48ce-4c03-844e-01371645ca1f
- date added to LUP
- 2024-06-05 14:40:04
- date last changed
- 2024-06-05 14:40:59
@article{7ba9fd36-48ce-4c03-844e-01371645ca1f,
abstract = {{<p>Therapeutic drug monitoring (TDM) of β-lactam antibiotics in critically ill patients may benefit dose optimization, thus improving therapeutic outcomes. However, rapidly and accurately detecting these antibiotics in blood remains a challenge. Our research group recently developed a thermometric biosensor called the New Delhi metallo-β-lactamase-1 (NDM-1) biosensor, which detected multiple classes of β-lactam antibiotics in spiked plasma samples. This study assesses the NDM-1 biosensor's effectiveness in detecting plasma concentrations of β-lactam antibiotic in treated patients. Seven patients receiving Cefuroxime were studied. Plasma samples collected pre- and post-antibiotic treatment were analyzed using the NDM-1 biosensor and compared with liquid chromatography coupled with ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). The biosensor detected plasma samples without dilution, and a brief pre-treatment using a PVDF filter significantly lowered matrix effects, reducing the running time to 5-8 minutes per sample. The assay's linear range for Cefuroxime (6.25 to 200 mg/L) covered target concentrations during the trough phase of pharmacokinetics in critically ill patients. The pharmacokinetic properties of Cefuroxime in treated patients determined by the NDM-1 biosensor and the UPLC-MS/MS were comparable, and the Cefuroxime plasma concentrations measured by the two methods showed a statistically good consistency. These data demonstrate that the NDM-1 biosensor assay is a fast, sensitive, and accurate method for detecting Cefuroximeplasma concentration in treated patients and highlights the NDM-1 biosensor as a promising tool for on-site TDM of β-lactam antibiotics in critically ill patients.</p>}},
author = {{Meng, Qinglai and Wang, Yao and Long, Yali and Wang, Qi and Gao, Yajing and Tian, Junsheng and Wu, Changxin and Xie, Bin}},
issn = {{1872-7913}},
language = {{eng}},
month = {{05}},
publisher = {{Elsevier}},
series = {{International Journal of Antimicrobial Agents}},
title = {{The NDM-1 biosensor rapidly and accurately detected antibiotic plasma concentrations in Cefuroxime-treated patients}},
url = {{http://dx.doi.org/10.1016/j.ijantimicag.2024.107229}},
doi = {{10.1016/j.ijantimicag.2024.107229}},
year = {{2024}},
}